Cargando…

Repression of YAP by NCTD disrupts NSCLC progression

The efficacy of available lung cancer therapeutic interference is significantly limited by various resistance mechanisms to those drugs. Activation of the oncogene YAP underlying the initiation, progression, and metastasis of lung cancer associates with poor prognosis and confers drug resistance aga...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Jiwei, Wu, Yan, Yang, Lijuan, Du, Jing, Gong, Kaikai, Chen, Weiwei, Dai, Juanjuan, Li, XueLin, Xi, Sichuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356801/ https://www.ncbi.nlm.nih.gov/pubmed/27903989 http://dx.doi.org/10.18632/oncotarget.13668

Ejemplares similares

Metformin-repressed miR-381-YAP-snail axis activity disrupts NSCLC growth and metastasis
por: Jin, Dan, et al.
Publicado: (2020)

Correction: Metformin-repressed miR-381-YAP-snail axis activity disrupts NSCLC growth and metastasis
por: Jin, Dan, et al.
Publicado: (2022)

Deregulation of UBE2C-mediated autophagy repression aggravates NSCLC progression
por: Guo, Jiwei, et al.
Publicado: (2018)

Disruption of SHH signaling cascade by SBE attenuates lung cancer progression and sensitizes DDP treatment
por: Du, Jing, et al.
Publicado: (2017)

m(6)A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2–mediated YAP activity in NSCLC
por: Jin, Dan, et al.
Publicado: (2020)

Correction: m6A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2–mediated YAP activity in NSCLC
por: Jin, Dan, et al.
Publicado: (2022)

Author Correction: Disruption of SHH signaling cascade by SBE attenuates lung cancer progression and sensitizes DDP treatment
por: Du, Jing, et al.
Publicado: (2020)

Aaptamine attenuates the proliferation and progression of non-small cell lung carcinoma
por: Gong, Kaikai, et al.
Publicado: (2020)

The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells
por: Guo, Jiwei, et al.
Publicado: (2018)

Retraction notice to ‘The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells’ [EBioMedicine 35 (2018) 204–221]
por: Guo, Jiwei, et al.
Publicado: (2021)

LncRNA MALAT1 Regulating Lung Carcinoma Progression via the miR-491-5p/UBE2C Axis
por: Dai, Juanjuan, et al.
Publicado: (2021)

Suppression of YAP by DDP disrupts colon tumor progression
por: Li, Kun, et al.
Publicado: (2018)

Suppression of YAP by DDP disrupts colon tumor progression
por: Li, Kun, et al.
Publicado: (2021)

Involvement of mitochondrial pathway in NCTD-induced cytotoxicity in human hepG2 cells
por: Chang, Cheng, et al.
Publicado: (2010)

The antineoplastic drug metformin downregulates YAP by interfering with IRF-1 binding to the YAP promoter in NSCLC
por: Jin, Dan, et al.
Publicado: (2018)

m(6)A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis
por: Jin, Dan, et al.
Publicado: (2019)

m(6)A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis
por: Jin, Dan, et al.
Publicado: (2021)

NCTD Prevents Renal Interstitial Fibrosis via Targeting Sp1/lncRNA Gm26669 Axis
por: Tian, Jiao, et al.
Publicado: (2021)

Correction to: m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis
por: Jin, Dan, et al.
Publicado: (2020)

NCTD promotes Birinapant-mediated anticancer activity in breast cancer cells by downregulation of c-FLIP
por: Zhao, Li, et al.
Publicado: (2017)

Retraction Note: m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis
por: Jin, Dan, et al.
Publicado: (2023)

Retraction notice to ‘The antineoplastic drug metformin downregulates YAP by interfering with IRF-1 binding to the YAP promoter in NSCLC’ [EBioMedicine 37 (2018) 188–204]
por: Jin, Dan, et al.
Publicado: (2021)

Enhanced nuclear localization of YAP1‐2 contributes to EGF‐induced EMT in NSCLC
por: Guo, Qiang, et al.
Publicado: (2022)

Norcantharidin Nanostructured Lipid Carrier (NCTD-NLC) Suppresses the Viability of Human Hepatocellular Carcinoma HepG2 Cells and Accelerates the Apoptosis
por: Yan, Zijun, et al.
Publicado: (2022)

SU4312 Represses Glioma Progression by Inhibiting YAP and Inducing Sensitization to the Effect of Temozolomide
por: Wang, Xu, et al.
Publicado: (2022)

YAP regulates PD-L1 expression in human NSCLC cells
por: Miao, Jinbai, et al.
Publicado: (2017)

NCTD elicits proapoptotic and antiglycolytic effects on colorectal cancer cells via modulation of Fam46c expression and inhibition of ERK1/2 signaling
por: Zhang, Shiqiang, et al.
Publicado: (2020)

[Retracted] NCTD elicits proapoptotic and antiglycolytic effects on colorectal cancer cells via modulation of Fam46c expression and inhibition of ERK1/2 signaling
por: Zhang, Shiqiang, et al.
Publicado: (2023)

Inhibiting YAP expression suppresses pancreatic cancer progression by disrupting tumor-stromal interactions
por: Jiang, Zhengdong, et al.
Publicado: (2018)

YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC
por: Ghiso, Elena, et al.
Publicado: (2017)

Structural basis and molecular mechanism of biased GPBAR signaling in regulating NSCLC cell growth via YAP activity
por: Ma, Lijuan, et al.
Publicado: (2022)

YAP at the progression of inflammation
por: Chen, Libin, et al.
Publicado: (2023)

RNF31 represses cell progression and immune evasion via YAP/PD-L1 suppression in triple negative breast Cancer
por: Yang, Huijie, et al.
Publicado: (2022)

Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells
por: You, Bin, et al.
Publicado: (2015)

Transcriptional repression induces a slowly progressive atypical neuronal death associated with changes of YAP isoforms and p73
por: Hoshino, Masataka, et al.
Publicado: (2006)

Transcriptional repression of beige fat innervation via a YAP/TAZ-S100B axis
por: Huang, Xun, et al.
Publicado: (2023)

NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors
por: McGowan, Marc, et al.
Publicado: (2017)

The Biology and Therapeutic Potential of the Src-YAP Axis in Non-Small Cell Lung Cancer (NSCLC)
por: Papavassiliou, Kostas A., et al.
Publicado: (2022)

miR-146a-5p targets TCSF and influences cell growth and apoptosis to repress NSCLC progression
por: Huang, Wen-Ting, et al.
Publicado: (2019)

Homeobox A4 suppresses vascular remodeling by repressing YAP/TEAD transcriptional activity
por: Kimura, Masahiro, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_71k44395rf9rbvtbf1plkjor8u